Since inhibition of the UPR by inhibiting IRE1α enhances cytotoxicity induced by proteasome inhibitors [27], these data suggest another mechanism whereby WT161 enhances bortezomib-induced cytotoxicity in breast cancer cells. Here, ERN1 is linked to breast carcinoma.